Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model

American Journal of Pathology

Volumn 185, Issue 2, 2015, Pages 347-355

  Pavlov, Vasile I ^a   Tan, Ying S ^a   McClure, Erin E ^a   La Bonte, Laura R ^a   Zou, Chenhui ^a   Gorsuch, William B ^a   Stahl, Gregory L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; MANNOSE BINDING LECTIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; UNCLASSIFIED DRUG; MANNOSE BINDING LECTIN; MANNOSE BINDING PROTEIN A; MBL2 PROTEIN, HUMAN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; COMPLEMENT DEPOSITION; COMPLEMENT LECTIN PATHWAY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBRIN DEPOSITION; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HYPERGLYCEMIA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPERFUSION INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE MODEL; GENE TARGETING; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; PROMOTER REGION; THROMBOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HUMANS; MANNOSE-BINDING LECTIN; MICE; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; PROMOTER REGIONS, GENETIC; THROMBOSIS;

EID: 84922275548     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.10.015     Document Type: Article

References (61)

1. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol 2002, 20:197-216
2. Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, Buras JA, Meri S, Stahl GL: Complement activation following oxidative stress: role of the lectin complement pathway. Am J Pathol 2000, 156:1549-1556
3. Fujita T: Evolution of the lectin-complement pathway and its role in innate immunity. Nat Rev Immunol 2002, 2:346-353
4. Schwaeble W, Dahl MR, Thiel S, Stover C, Jensenius JC: The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes. Immunobiology 2002, 205:455-466
5. McMullen ME, Hart ML, Walsh MC, Buras J, Takahashi K, Stahl GL: Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo. Immunobiology 2006, 211: 759-766
6. Liu H, Jensen L, Hansen S, Petersen SV, Takahashi K, Ezekowitz AB, Hansen FD, Jensenius JC, Thiel S: Characterization and quantification of mouse mannan-binding lectins (MBL-A and MBL-C) and study of acute phase responses. Scand J Immunol 2001, 53:489-497
7. Hansen S, Selman L, Palaniyar N, Ziegler K, Brandt J, Kliem A, Jonasson M, Skjoedt MO, Nielsen O, Hartshorn K, Jorgensen TJD, Skjodt K, Holmskov U: Collectin 11 (CL-11, CL-K1) is a MASP-1/- 3-associated plasma collectin with microbial-binding activity. J Immunol 2010, 185:6096-6104
8. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KB, Jensenius JC: A second serine protease associated with mannanbinding lectin that activates complement. Nature 1997, 386:506-510
9. Takahashi M, Endo Y, Fujita T, Matsushita M: A truncated form of mannose-binding lectin-associated serine protease (MASP)-2 expressed by alternative polyadenylation is a component of the lectin complement pathway. Int Immunol 1999, 11:859-863
10. Stover CM, Thiel S, Lynch NJ, Schwaeble WJ: The rat and mouse homologues of MASP-2 and MAp19, components of the lectin activation pathway of complement. J Immunol 1999, 163:6848-6859
11. Chen CB, Wallis R: Two mechanisms for mannose-binding protein modulation of the activity of its associated serine proteases. J Biol Chem 2004, 279:26058-26065
12. Iwaki D, Kanno K, Takahashi M, Endo Y, Lynch NJ, Schwaeble WJ, Matsushita M, Okabe M, Fujita T: Small mannose-binding lectinassociated protein plays a regulatory role in the lectin complement pathway. J Immunol 2006, 177:8626-8632
13. Takahashi M, Iwaki D, Kanno K, Ishida Y, Xiong J, Matsushita M, Endo Y, Miura S, Ishii N, Sugamura K, Fujita T: Mannose-binding lectin (MBL)-associated serine protease (MASP)-1 contributes to activation of the lectin complement pathway. J Immunol 2008, 180: 6132-6138
14. Degn SE, Hansen AG, Steffensen R, Jacobsen C, Jensenius JC, Thiel S: MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J Immunol 2009, 183:7371-7378
15. Skjoedt MO, Hummelshoj T, Palarasah Y, Honore C, Koch C, Skjodt K, Garred P: A novel MBL/ficolin associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation. J Biol Chem 2010, 285:8234-8243
16. Takahashi M, Ishida Y, Iwaki D, Kanno K, Suzuki T, Endo Y, Homma Y, Fujita T: Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J Exp Med 2010, 207:29-33
17. Iwaki D, Kanno K, Takahashi M, Endo Y, Matsushita M, Fujita T: The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J Immunol 2011, 187:3751-3758
18. Jordan JE, Montalto MC, Stahl GL: Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001, 104:1413-1418
19. Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, Solomon SD, Ezekowitz RA, Stahl GL: Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immunol 2005, 175:541-546
20. Busche MN, Walsh MC, McMullen ME, Guikema BJ, Stahl GL: Mannose-binding lectin plays a critical role in myocardial ischaemia and reperfusion injury in a mouse model of diabetes. Diabetologia 2008, 51:1544-1551
21. La Bonte LR, Pavlov VI, Tan YS, Takahashi K, Takahashi M, Banda NK, Zou C, Fujita T, Stahl GL: Mannose-binding lectinassociated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis. J Immunol 2012, 188:885-891
22. Pavlov VI, Skjoedt M-O, Tan YS, Rosbjerg A, Garred P, Stahl GL: Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation 2012, 126:2227-2235
23. Committee for the Update of the Guide for the Care and Use of Laboratory Animals; National Research Council: Guide for the Care and Use of Laboratory Animals: Eighth Edition. Washington, DC, National Academies Press, 2011
24. Walsh MC, Shaffer LA, Guikema BJ, Body SC, Shernan SK, Fox AA, Collard CD, Fung M, Taylor RP, Stahl GL: Fluorochromelinked immunoassay for functional analysis of the mannose binding lectin complement pathway to the level of C3 cleavage. J Immunol Methods 2007, 323:147-159
25. Pavlov VI, La Bonte LR, Baldwin WM, Markiewski M, Lambris J, Stahl GL: Absence of mannose-binding lectin prevents hyperglycemic cardiovascular complications. Am J Pathol 2012, 180:104-112
26. Gorsuch WB, Guikema BJ, Fritzinger DC, Vogel C-W, Stahl GL: Humanized cobra venom factor decreases myocardial ischemiareperfusion injury. Mol Immunol 2009, 47:506-510
27. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL: Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998, 97:2259-2267
28. Wang X, Xu L: An optimized murine model of ferric chlorideinduced arterial thrombosis for thrombosis research. Thromb Res 2005, 115:95-100
29. Westrick RJ, Winn ME, Eitzman DT: Murine models of vascular thrombosis (Eitzman series). Arterioscler Thromb Vasc Biol 2007, 27:2079-2093
30. Weiler-Guettler H, Christie PD, Beeler DL, Healy AM, Hancock WW, Rayburn H, Edelberg JM, Rosenberg RD: A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J Clin Invest 1998, 101:1983-1991
31. Takahashi K, Chang WC, Takahashi M, Pavlov V, Ishida Y, La Bonte LR, Shi L, Fujita T, Stahl GL, Van Cott EM: Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology 2011, 216:96-102
32. Orsini F, Villa P, Parrella S, Zangari R, Zanier ER, Gesuete R, Stravalaci M, Fumagalli S, Ottria R, Reina JJ, Paladini A, Micotti E, Ribeiro-Viana R, Rojo J, Pavlov VI, Stahl GL, Bernardi A, Gobbi M, De Simoni MG: Targeting mannose-binding lectin confers longlasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation 2012, 126:1484-1494
33. Martel C, Granger CB, Ghitescu M, Stebbins A, Fortier A, Armstrong PW, Bonnefoy A, Theroux P: Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with STelevation myocardial infarction undergoing primary percutaneous coronary intervention: insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am Heart J 2012, 164:43-51
34. Trendelenburg M, Theroux P, Stebbins A, Granger C, Armstrong P, Pfisterer M: Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute STelevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J 2010, 31:1181-1187
35. Osthoff M, Katan M, Fluri F, Schuetz P, Bingisser R, Kappos L, Steck AJ, Engelter ST, Mueller B, Christ-Crain M, Trendelenburg M: Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS One 2011, 6:e21338
36. Gulla KC, Gupta K, Krarup A, Gal P, Schwaeble WJ, Sim RB, O'Connor CD, Hajela K: Activation of mannan-binding lectinassociated serine proteases leads to generation of a fibrin clot. Immunology 2010, 129:482-495
37. Presanis JS, Hajela K, Ambrus G, Gál P, Sim RB: Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol Immunol 2004, 40:921-929
38. Morita T, Kato H, Iwanaga S, Takada K, Kimura T, Sakakibara S: New fluorogenic substrates for a-thrombin, factor Xa, kallikreins, and urokinase. J Biochem 1977, 82:1495-1498
39. Krarup A, Wallis R, Presanis JS, Gal P, Sim RB: Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One 2007, 2:e623
40. Hess K, Ajjan R, Phoenix F, Dobo J, Gal P, Schroeder V: Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS One 2012, 7:e35690
41. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, Niho Y: C5a induces tissue factor activity on endothelial cells. Thromb Haemost 1997, 77:394-398
42. Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, Rafail S, Kartalis G, Sideras P, Lambris JD: A novel C5a receptortissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006, 177:4794-4802
43. Kambas K, Markiewski MM, Pneumatikos IA, Rafail SS, Theodorou V, Konstantonis D, Kourtzelis I, Doumas MN, Magotti P, DeAngelis RA, Lambris JD, Ritis KD: C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome. J Immunol 2008, 180:7368-7375
44. Wojta J, Kaun C, Zorn G, Ghannadan M, Hauswirth AW, Sperr WR, Fritsch G, Printz D, Binder BR, Schatzl G, Zwirner J, Maurer G, Huber K, Valent P: C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 2002, 100:517-523
45. Markiewski MM, DeAngelis RA, Lambris JD: Liver inflammation and regeneration: two distinct biological phenomena or parallel pathophysiologic processes? Mol Immunol 2006, 43:45-56
46. Markiewski MM, DeAngelis RA, Strey CW, Foukas PG, Gerard C, Gerard N, Wetsel RA, Lambris JD: The regulation of liver cell survival by complement. J Immunol 2009, 182:5412-5418
47. Levi M, van der Poll T: Two-way interactions between inflammation and coagulation. Trends Cardiovasc Med 2005, 15:254-259
48. Shebuski RJ, Kilgore KS: Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002, 300:729-735
49. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U: Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 2005, 96:1233-1239
50. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD: Complement and coagulation: strangers or partners in crime? Trends Immunol 2007, 28:184-192
51. Nangaku M, Couser WG: Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005, 9: 183-191
52. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A: The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997, 185:1619-1627
53. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Bruckner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M: Molecular intercommunication between the complement and coagulation systems. J Immunol 2010, 185:5628-5636
54. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA: Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006, 12:682-687
55. Lidington EA, Haskard DO, Mason JC: Induction of decayaccelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 2000, 96: 2784-2792
56. Ekdahl KN, Nilsson B: Phosphorylation of complement component C3 and C3 fragments by a human platelet protein kinase: inhibition of factor I-mediated cleavage of C3b. J Immunol 1995, 154: 6502-6510
57. Nilsson-Ekdahl K, Nilsson B: Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1. Eur J Immunol 2001, 31:1047-1054
58. Shats-Tseytlina EA, Nair CH, Dhall DP: Complement activation: a new participant in the modulation of fibrin gel characteristics and the progression of atherosclerosis? Blood Coagul Fibrinolysis 1994, 5: 529-535
59. Weiler JM, Linhardt RJ: Antithrombin III regulates complement activity in vitro. J Immunol 1991, 146:3889-3894
60. Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP: Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992, 148:3210-3215
61. Wang X: Experimental mouse models of thrombosis optimized for drug discovery and development. Lett Drug Des Discov 2005, 2: 403-411